Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abacavir Sulfate

FDA-approved product (tablet, oral), marketed as Abacavir Sulfate, Ziagen.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Abacavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abacavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abacavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

    NCT01077557 · start 2006-11

    Registered record
    Registry ID
    NCT01077557
    Conditions
    Fracture; Infection, Human Immunodeficiency Virus
    Interventions
    No Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug Exposure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-11
    Completion
    2011-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFracture; Infection, Human Immunodeficiency Virus
    InterventionNo Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug Exposure
    PhaseNot recorded
    Registry statusCompleted

  • HLA-B*5701 And Hypersensitivity To Abacavir

    NCT00373945 · start 2006-08

    Registered record
    Registry ID
    NCT00373945
    Conditions
    HIV Infection
    Interventions
    Observational Study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-08
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionObservational Study
    PhaseNot recorded
    Registry statusCompleted

  • PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months

    NCT01973439 · start 2006-07

    Registered record
    Registry ID
    NCT01973439
    Conditions
    HIV Infection
    Interventions
    Intervention 1: PK assessment while on Twice Daily Abacavir; Intervention 2: PK assessment while on Once Daily Abacavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2009-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionIntervention 1: PK assessment while on Twice Daily Abacavir; Intervention 2: PK assessment while on Once Daily Abacavir
    PhasePhase 1
    Registry statusCompleted

  • Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

    NCT00270296 · start 2006-06

    Registered record
    Registry ID
    NCT00270296
    Conditions
    HIV Infections
    Interventions
    Trizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-09
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTrizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults

    NCT00449436 · start 2005-01-10

    Registered record
    Registry ID
    NCT00449436
    Conditions
    HIV Infections
    Interventions
    TRIZIVIR; Non-nucleoside reverse transcriptase inhibitor; Boosted Protease Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01-10
    Completion
    2007-12-13
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTRIZIVIR; Non-nucleoside reverse transcriptase inhibitor; Boosted Protease Inhibitor
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients

    NCT00318123 · start 2004-04

    Registered record
    Registry ID
    NCT00318123
    Conditions
    HIV Infections
    Interventions
    Kivexa
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2007-04
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionKivexa
    PhasePhase 3
    Registry statusCompleted

  • Botanical/Drug Interactions in HIV: Glucuronidation

    NCT00065741 · start 2003-09

    Registered record
    Registry ID
    NCT00065741
    Conditions
    HIV Seronegativity
    Interventions
    silymarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-09
    Completion
    2006-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seronegativity
    Interventionsilymarin
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

    NCT00044577 · start 2002-07-16

    Registered record
    Registry ID
    NCT00044577
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    abacavir/lamivudine; abacavir; lamivudine; tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-07-16
    Completion
    2004-05-25
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    Interventionabacavir/lamivudine; abacavir; lamivudine; tenofovir
    PhasePhase 3
    Registry statusCompleted

  • Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

    NCT00038506 · start 2002-03

    Registered record
    Registry ID
    NCT00038506
    Conditions
    HIV Infection
    Interventions
    abacavir/lamivudine/zidovudine; tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2004-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Interventionabacavir/lamivudine/zidovudine; tenofovir
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients

    NCT02995824 · start 2002-01

    Registered record
    Registry ID
    NCT02995824
    Conditions
    Liver Transplantation; HIV Infections; Antiretroviral Therapy
    Interventions
    Raltegravir-based antiretroviral therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-01
    Completion
    2019-12-31
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; HIV Infections; Antiretroviral Therapy
    InterventionRaltegravir-based antiretroviral therapy
    PhaseNot recorded
    Registry statusCompleted

  • A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

    NCT00002163

    Registered record
    Registry ID
    NCT00002163
    Conditions
    AIDS Dementia Complex; HIV Infections
    Interventions
    Abacavir sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS Dementia Complex; HIV Infections
    InterventionAbacavir sulfate
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

    NCT00002183

    Registered record
    Registry ID
    NCT00002183
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    PhasePhase 1
    Registry statusCompleted

  • An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

    NCT00002205

    Registered record
    Registry ID
    NCT00002205
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Amprenavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Amprenavir
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

    NCT00002217

    Registered record
    Registry ID
    NCT00002217
    Conditions
    HIV Infections
    Interventions
    Lamivudine/Zidovudine; Abacavir sulfate; Amprenavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamivudine/Zidovudine; Abacavir sulfate; Amprenavir
    PhaseNot applicable
    Registry statusCompleted